CA3058272A1 — Pharmaceutical composition containing mor agonist and kor agonist, and uses thereof
Assigned to Jiangsu Hengrui Medicine Co Ltd · Expires 2018-10-18 · 8y expired
What this patent protects
Provided are uses of the combination of a .mu. opioid receptor (MOR) agonist and a .kappa. opioid receptor (KOR) agonist in the preparation of drugs for relieving and/or treating pain. The MOR agonist is selected from the compound represented in formula (I), or a tautomer, mesome…
USPTO Abstract
Provided are uses of the combination of a .mu. opioid receptor (MOR) agonist and a .kappa. opioid receptor (KOR) agonist in the preparation of drugs for relieving and/or treating pain. The MOR agonist is selected from the compound represented in formula (I), or a tautomer, mesomer, racemate, enantiomer or diastereomer thereof, or a mixture thereof, or a pharmaceutically acceptable salt thereof. Also provided is a pharmaceutical composition containing the MOR agonist and the KOR agonist. (see above formula)
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.